
|Videos|April 4, 2017
Treatment of Gastroesophageal Junction Carcinoma
Author(s)Ian Chau, MD
This video reviews first- and second-line treatment options for patients with carcinoma of the gastroesophageal junction.
Advertisement
In this video, Ian Chau, MD, of Royal Marsden Hospital in London, reviews first- and second-line treatment options for patients with carcinoma of the gastroesophageal junction.
In the first-line setting, different standards for treatment duration exist around the world, including the idea of rechallenging with the same chemotherapy if a patient achieves stable disease.
In the second-line setting, Chau discusses the use of chemotherapy and ramucirumab.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts NDA for Daraxonrasib in Pretreated Metastatic Pancreatic Cancer
2
CAR T-Cell Expansion Predicts Toxicity, But Not Always Efficacy
3
Mapping the Full CAR T-Cell Journey in DLBCL From Referral to Survivorship
4
Consolidative Radiotherapy Adds Toxicity Without Survival Benefit in SCLC
5





















































